Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $5.3 million.

  • Vanda Pharmaceuticals' Other Operating Expenses rose 2943.63% to $5.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.9 million, marking a year-over-year increase of 712.95%. This contributed to the annual value of $18.9 million for FY2025, which is 712.95% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Other Operating Expenses stood at $5.3 million for Q4 2025, which was up 2943.63% from $4.4 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Other Operating Expenses registered a high of $6.8 million during Q3 2021, and its lowest value of $3.2 million during Q3 2023.
  • In the last 5 years, Vanda Pharmaceuticals' Other Operating Expenses had a median value of $5.1 million in 2024 and averaged $5.1 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Other Operating Expenses plummeted by 4932.81% in 2023, and later surged by 2943.63% in 2025.
  • Vanda Pharmaceuticals' Other Operating Expenses (Quarter) stood at $6.2 million in 2021, then rose by 1.64% to $6.3 million in 2022, then plummeted by 33.55% to $4.2 million in 2023, then fell by 3.04% to $4.1 million in 2024, then rose by 29.44% to $5.3 million in 2025.
  • Its Other Operating Expenses stands at $5.3 million for Q4 2025, versus $4.4 million for Q3 2025 and $4.2 million for Q2 2025.